NHL Cyberfamily

Non-Hodgkin's lymphoma support


Novel stem cell transplant protocols


New and improved SCT protocols

The field of Stem Cell Transplants is expanding rapidly. What was once reserved for only the most desperate patients with aggressive lymphoma has become a standard therapy for virtually any type of Lymphoma.

In the past patients with indolent types of lymphoma such as follicular NHL rarely underwent a Stem Cell Transplant until they had tried at least 3-4 other therapies. The wisdom of the time was that this very aggressive treatment should not be used when less toxic and less risky treatments were still available.

This thinking has changed quite dramatically in the past decade. Since about the early 2000's there have been many novel new approaches to SCT's that combine immunotherapy in the form of Rituxan, Zevalin, Bexxar, Interferon and others, which have proven to dramatically improve the progression free survival for patients with indolent lymphoma. Immunotherapy combined with chemotherapy is becoming the wave of the future.

Another exciting prospect is the use of Chimeric Antigen Receptor T-cell therapy. (CAR-T cell therapy) While this is an early science as of 2016 the preliminary results are quite exciting. The first link below uses CAR T-cells in the SCT protocol.

Below are some selected medical abstracts about some of these new SCT protocols. These will be updated from time to time to keep them current. 

  1. Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL

  2. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma

  3. Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial

  4. High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation

  5. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study

  6. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas